Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced it will report its second quarter 2024 financial results on August 14, 2024, after the U.S. financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to provide a business update. Investors can access the conference call via phone or webcast, with an archived replay available on the company's website afterward. Longeveron focuses on developing cellular therapies for life-threatening and chronic aging-related conditions.

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call Details:
Conference Call Number:	1.877.407.0789
Conference ID:	13747923
Call me™ Feature:	Click Here
Webcast:	Click Here

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease (AD), and Aging-related Frailty. Lomecel-B^TM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

When will Longeveron (LGVN) report its Q2 2024 financial results?

Longeveron (LGVN) will report its second quarter 2024 financial results on Wednesday, August 14, 2024, after the U.S. financial markets close.

What time is Longeveron's (LGVN) Q2 2024 earnings call scheduled for?

Longeveron's (LGVN) Q2 2024 earnings call is scheduled for Wednesday, August 14, 2024, at 4:30 p.m. ET.

How can investors access Longeveron's (LGVN) Q2 2024 earnings call?

Investors can access Longeveron's (LGVN) Q2 2024 earnings call via phone using the conference call number 1.877.407.0789 and Conference ID 13747923, or through the webcast link provided on the company's website.

What is the main focus of Longeveron's (LGVN) business?

Longeveron (LGVN) is a clinical stage regenerative medicine biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions.